BIH Digital Health Accelerator Program 2024
Application Deadline: Friday, 3 November, 2023 at 6pm (CET)
1 Min
More 
Researchers from Charité and the University of Calgary discover new type of cells
A team of researchers has uncovered a previously unknown compensatory mechanism found in liver disease. If Kupffer cells (KCs), a specific kind of immune cells found in the liver, become impaired by tissue scarring, immune cells originating in the…
5 Min
More Eckert & Ziegler Receives Award for Professional Training
Eckert & Ziegler AG has been awarded the Pankow 2023 Training Prize for outstanding training quality. The award was presented yesterday at a celebration event by Berlin-Pankow District Mayor Dr. Cordelia Koch.
2 Min
More Starting up with highly promising immunotherapies
After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help…
3 Min
More Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
Collaboration will develop and market Satellite Hot Labs for radiolabeling of BioGuides
5 Min
More In Portrait | Berlin Center for Advanced Therapies (BeCAT) at the Charité
BeCAT - The therapy of the future is developed here
At Charité's "Berlin Center for Advanced Therapies" (BeCAT), the new class of Advanced Therapy Medicinal Products (ATMP) has been under development since 2018. In 2024, it will move into the new…
5 Min
More Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
The patient population that benefits most from treatment with enibarcimab in septic shock can be clearly defined by two biomarkers, according to data presented today
In the AdrenOSS-2 study, the relevant subgroup had a significant reduction in…
6 Min
More PRAMOMOLECULAR wants to silence cancer
PRAMOMOLECULAR GmbH, a spin-off of the Technische Universität Berlin, uses gene silencing to down-regulate cancer proteins and thus reduce tumor growth. This makes it possible to address cancers in a well-tolerated and targeted manner that cannot be…
2 Min
More ERC Starting Grants for two Charité researchers
Two researchers, one from Charité – Universitätsmedizin Berlin and one from the Berlin Institute of Health at Charité (BIH), have been selected for grants by the European Research Council for their ideas. Dr. Birgit Nemec holds the position of…
5 Min
More In Portrait | The Research Center "Der Simulierte Mensch” (The Simulated Human) (Si-M)
Another center for cutting-edge research in medicine is being built in Berlin. The new building, called "Der Simulierte Mensch" (Si-M), will provide space for around 140 researchers from science and clinical practice to carry out their scientific…
4 Min
More Show more items
